• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有细胞毒性和 CDK2 激酶抑制活性的一系列色酮腙类化合物:一种潜在的 II 型 ATP 竞争性抑制剂。

A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor.

机构信息

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

College of Pharmacy, Yeungnam University, Gyeongsan 38541, Korea.

出版信息

Molecules. 2020 Sep 25;25(19):4400. doi: 10.3390/molecules25194400.

DOI:10.3390/molecules25194400
PMID:32992673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7582667/
Abstract

Isatin derivatives potentially act on various biological targets. In this article, a series of novel isatin-hydrazones were synthesized in excellent yields. Their cytotoxicity was tested against human breast adenocarcinoma (MCF7) and human ovary adenocarcinoma (A2780) cell lines using MTT assay. Compounds (IC = 1.51 ± 0.09 µM) and (IC = 3.56 ± 0.31) showed excellent activity against MCF7, whereas compound showed considerable cytotoxicity against both tested cell lines, MCF7 (IC = 5.46 ± 0.71 µM) and A2780 (IC = 18.96± 2.52 µM), respectively. Structure-activity relationships (SARs) revealed that, halogen substituents at 2,6-position of the C-ring of isatin-hydrazones are the most potent derivatives. In-silico absorption, distribution, metabolism and excretion (ADME) results demonstrated recommended drug likeness properties. Compounds (IC = 0.245 µM) and (IC = 0.300 µM) exhibited good inhibitory activity against the cell cycle regulator CDK2 protein kinase compared to imatinib (IC = 0.131 µM). A molecular docking study of and confirmed both compounds as type II ATP competitive inhibitors that made interactions with ATP binding pocket residues, as well as lacking interactions with active state DFG motif residues.

摘要

靛红衍生物可能作用于多种生物靶点。在本文中,我们以优异的产率合成了一系列新型的靛红腙。采用 MTT 法检测它们对人乳腺癌(MCF7)和人卵巢腺癌(A2780)细胞系的细胞毒性。化合物 (IC = 1.51 ± 0.09 μM)和 (IC = 3.56 ± 0.31)对 MCF7 表现出优异的活性,而化合物 对两种测试的细胞系 MCF7(IC = 5.46 ± 0.71 μM)和 A2780(IC = 18.96 ± 2.52 μM)均显示出相当的细胞毒性。构效关系(SAR)表明,C 环上 2,6 位取代的卤素取代基是最有效的衍生物。基于计算机的吸收、分布、代谢和排泄(ADME)结果表明具有推荐的药物相似性特性。化合物 (IC = 0.245 μM)和 (IC = 0.300 μM)对细胞周期调节因子 CDK2 蛋白激酶的抑制活性优于伊马替尼(IC = 0.131 μM)。与 和 的分子对接研究证实,这两种化合物均为 II 型 ATP 竞争性抑制剂,与 ATP 结合口袋残基相互作用,而与活性状态 DFG 基序残基缺乏相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/6ec16739f0b1/molecules-25-04400-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/e68cd657bf50/molecules-25-04400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/b8c986634dd1/molecules-25-04400-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/323b996aba2a/molecules-25-04400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/b41079c47ead/molecules-25-04400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/6ec16739f0b1/molecules-25-04400-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/e68cd657bf50/molecules-25-04400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/b8c986634dd1/molecules-25-04400-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/323b996aba2a/molecules-25-04400-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/b41079c47ead/molecules-25-04400-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/7582667/6ec16739f0b1/molecules-25-04400-g004.jpg

相似文献

1
A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor.具有细胞毒性和 CDK2 激酶抑制活性的一系列色酮腙类化合物:一种潜在的 II 型 ATP 竞争性抑制剂。
Molecules. 2020 Sep 25;25(19):4400. doi: 10.3390/molecules25194400.
2
Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents.具有新型连接基的双异吲哚啉腙类化合物:作为细胞毒性剂的合成与生物学评价
Eur J Med Chem. 2016 Jan 27;108:415-422. doi: 10.1016/j.ejmech.2015.11.047. Epub 2015 Dec 2.
3
Quinazolin-4(3)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity.基于喹唑啉-4(3)-酮的具有优异细胞毒性的潜在多靶点酪氨酸激酶抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2055-2067. doi: 10.1080/14756366.2021.1972992.
4
Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.新型吡唑并[3,4-d]嘧啶类化合物作为潜在的细胞毒剂:设计、合成、分子对接和 CDK2 抑制。
Anticancer Agents Med Chem. 2019;19(11):1368-1381. doi: 10.2174/1871520619666190417153350.
5
Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.新型噻吗啉连接的色酮腙作为潜在的耐药结核分枝杆菌抑制剂。
Bioorg Chem. 2021 Oct;115:105133. doi: 10.1016/j.bioorg.2021.105133. Epub 2021 Jul 3.
6
New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.新型噻唑-腙-香豆素杂合体靶向人宫颈癌细胞:合成、CDK2 抑制、QSAR 和分子对接研究。
Bioorg Chem. 2019 May;86:80-96. doi: 10.1016/j.bioorg.2019.01.026. Epub 2019 Jan 19.
7
A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights.一种具有 3-腙基吲哚啉-2-酮骨架的新型 CDK2 抑制剂,具有抗乳腺癌活性:设计、合成、生物学评价和计算洞察。
Molecules. 2021 Jan 14;26(2):412. doi: 10.3390/molecules26020412.
8
Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and studies.新型吲哚并[3,2-b]呋喃类化合物作为潜在的双重 CDK2/GSK-3β抑制剂靶向乳腺癌的设计、合成、生物评价及研究
J Enzyme Inhib Med Chem. 2021 Dec;36(1):270-285. doi: 10.1080/14756366.2020.1862101.
9
Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.具有潜在 EGFR 抑制活性的新型(吗啉磺酰基)异吲哚啉酮的设计、合成、抗增殖活性、分子对接和细胞周期分析。
Eur J Med Chem. 2018 Aug 5;156:918-932. doi: 10.1016/j.ejmech.2018.06.061. Epub 2018 Jun 28.
10
Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.发现 3,6-二取代哒嗪类化合物作为新型靶向细胞周期蛋白依赖性激酶 2 的抗癌剂:合成、生物学评价和计算模拟研究。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1616-1630. doi: 10.1080/14756366.2020.1806259.

引用本文的文献

1
A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020-2025).基于异吲哚酮的化合物作为抗癌治疗通用框架的综合综述及最新进展(2020 - 2025年)
RSC Adv. 2025 Sep 8;15(39):32188-32231. doi: 10.1039/d5ra05002b. eCollection 2025 Sep 5.
2
Design and Synthesis of New 5-Methylisatin Derivatives as Potential CDK2 Inhibitors.新型5-甲基异吲哚酮衍生物作为潜在CDK2抑制剂的设计与合成
Int J Mol Sci. 2025 Feb 27;26(5):2144. doi: 10.3390/ijms26052144.
3
Molecular docking and synthesis of N-alkyl-isatin-3-imino aromatic amine derivatives and their antileishmanial and cytotoxic activities.

本文引用的文献

1
and metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling.瑞博西尼的代谢:一种用于阐明生物活化途径和代谢物谱分析的质谱方法。
RSC Adv. 2020 Jun 12;10(38):22668-22683. doi: 10.1039/d0ra01624a. eCollection 2020 Jun 10.
2
Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and toxicity studies of its metabolites.使用液相色谱-串联质谱法(LC-MS/MS)对X-376在人肝微粒体孵育中的I期代谢谱及意外反应性代谢产物进行研究:其代谢产物的生物活化途径阐明及毒性研究
RSC Adv. 2020 Feb 3;10(9):5412-5427. doi: 10.1039/c9ra09115g. eCollection 2020 Jan 29.
3
N-烷基异吲哚酮-3-亚氨基芳香胺衍生物的分子对接与合成及其抗利什曼原虫和细胞毒性活性
Res Pharm Sci. 2024 Apr 1;19(2):238-250. doi: 10.4103/RPS.RPS_244_22. eCollection 2024 Apr.
4
Investigation of Newly Synthesized Fluorinated Isatin-Hydrazones by Antiproliferative Activity, Molecular Docking, ADME Analysis, and e-Pharmacophore Modeling.通过抗增殖活性、分子对接、ADME分析和电子药效团建模对新合成的氟化异吲哚酮腙进行研究。
ACS Omega. 2024 Jun 5;9(24):26503-26518. doi: 10.1021/acsomega.4c03014. eCollection 2024 Jun 18.
5
Identification of dual-target isoxazolidine-isatin hybrids with antidiabetic potential: Design, synthesis, and multiscale molecular modeling approaches.具有抗糖尿病潜力的双靶点异恶唑烷-异吲哚酮杂化物的鉴定:设计、合成及多尺度分子建模方法
Heliyon. 2024 Feb 11;10(4):e25911. doi: 10.1016/j.heliyon.2024.e25911. eCollection 2024 Feb 29.
6
Evaluation of Anti-Neuroinflammatory Activity of Isatin Derivatives in Activated Microglia.评价色胺衍生物在激活的小神经胶质细胞中的抗神经炎症活性。
Molecules. 2023 Jun 20;28(12):4882. doi: 10.3390/molecules28124882.
7
Antidiabetic and Anticancer Potentials of L. from Different Geographical Origins.不同地理来源的[具体名称未给出,推测为某种植物,此处用L.代替]的抗糖尿病和抗癌潜力。
Pharmaceuticals (Basel). 2023 Feb 24;16(3):350. doi: 10.3390/ph16030350.
8
Biological Screening of L. from Different Origins for Antidiabetic and Anticancer Activity.对不同来源的L.进行抗糖尿病和抗癌活性的生物学筛选。
Pharmaceuticals (Basel). 2022 Dec 21;16(1):7. doi: 10.3390/ph16010007.
9
Anticancer Inhibitors.抗癌抑制剂。
Molecules. 2022 Jul 21;27(14):4650. doi: 10.3390/molecules27144650.
10
Evaluation of antioxidant and cytotoxic properties of phenolic -acylhydrazones: structure-activity relationship.酚酰腙类化合物的抗氧化和细胞毒性特性评估:构效关系
R Soc Open Sci. 2022 Jun 8;9(6):211853. doi: 10.1098/rsos.211853. eCollection 2022 Jun.
Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
发现 3,6-二取代哒嗪类化合物作为新型靶向细胞周期蛋白依赖性激酶 2 的抗癌剂:合成、生物学评价和计算模拟研究。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1616-1630. doi: 10.1080/14756366.2020.1806259.
4
Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.细胞周期蛋白依赖性激酶 2(CDK2)与特异性强效抑制剂 CVT-313 复合物的结构。
Acta Crystallogr F Struct Biol Commun. 2020 Aug 1;76(Pt 8):350-356. doi: 10.1107/S2053230X20009243. Epub 2020 Jul 28.
5
Novel [(-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and studies.新型[(-烷基-3-吲哚基亚甲基)腙基]氧吲哚通过抑制 CDK2 和 Bcl-2 来阻止细胞周期并诱导细胞凋亡:合成、生物学评价和研究。
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1300-1309. doi: 10.1080/14756366.2020.1773814.
6
Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.鉴定细胞周期蛋白依赖性激酶 2 的高亲和力抑制剂用于抗癌治疗。
Molecules. 2019 Dec 15;24(24):4589. doi: 10.3390/molecules24244589.
7
Isatin and its derivatives: a survey of recent syntheses, reactions, and applications.异吲哚酮及其衍生物:近期合成、反应及应用综述
Medchemcomm. 2019 Jan 15;10(3):351-368. doi: 10.1039/c8md00585k. eCollection 2019 Mar 1.
8
Isatin derivatives and their anti-bacterial activities.色胺衍生物及其抗菌活性。
Eur J Med Chem. 2019 Feb 15;164:678-688. doi: 10.1016/j.ejmech.2018.12.017. Epub 2018 Dec 9.
9
Novel hydrazido benzenesulfonamides-isatin conjugates: Synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies.新型腙苯磺酰胺-靛红衍生物的合成、碳酸酐酶抑制活性及分子模拟研究。
Eur J Med Chem. 2018 Sep 5;157:28-36. doi: 10.1016/j.ejmech.2018.07.054. Epub 2018 Jul 24.
10
Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implications.色胺酮,一种内源性非肽生物因子:综述其分子靶点、作用机制及对生物医学的影响。
Biofactors. 2018 Mar;44(2):95-108. doi: 10.1002/biof.1408. Epub 2018 Jan 16.